News

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...
Wall Street has no breathing room this week as August kicks off with a flood of economic data, high-stakes Fed talk, and ...